Abstract
The so-called “silver tsunami” is a metaphor that the individuals 65 and older represent the most rapidly growing segment of the Western world population.
Aging is an ongoing process that leads to the loss of functional reserve of multiple organ systems, increased susceptibility to stress, it is associated with increased prevalence of chronic disease, and functional dependence. Determined by a combination of genetic and environmental factors, this process is highly individualized and poorly reflected in chronologic age. The heterogeneity and the complexity of the older old population represent the main challenge to the treatment of cancer in those patients. We should discern "fit" elderly in whom standard cancer treatment appears to be comparable to a younger population and “unfit” or "frail" elderly, in which the risks of the treatment may overwhelm potential benefits.
There are many aspects that have to be assessed before treating an elderly patient, or before to choose the treatment itself. In our review we will try to explain and describe the meaning and the most important aspects related to the oldest old complex patients, and how to manage those patients.
Keywords: Cancer, elderly, oldest old, sarcopenia, fatigue, frailty, CGA.
Current Pharmaceutical Design
Title:Treating Cancer in Older and Oldest Old Patients
Volume: 21 Issue: 13
Author(s): G. Colloca, A. Corsonello, E. Marzetti, L. Balducci, F. Landi, M. Extermann, G. Scambia, M. Cesari, I. Carreca, S. Monfardini and R. Bernabei
Affiliation:
Keywords: Cancer, elderly, oldest old, sarcopenia, fatigue, frailty, CGA.
Abstract: The so-called “silver tsunami” is a metaphor that the individuals 65 and older represent the most rapidly growing segment of the Western world population.
Aging is an ongoing process that leads to the loss of functional reserve of multiple organ systems, increased susceptibility to stress, it is associated with increased prevalence of chronic disease, and functional dependence. Determined by a combination of genetic and environmental factors, this process is highly individualized and poorly reflected in chronologic age. The heterogeneity and the complexity of the older old population represent the main challenge to the treatment of cancer in those patients. We should discern "fit" elderly in whom standard cancer treatment appears to be comparable to a younger population and “unfit” or "frail" elderly, in which the risks of the treatment may overwhelm potential benefits.
There are many aspects that have to be assessed before treating an elderly patient, or before to choose the treatment itself. In our review we will try to explain and describe the meaning and the most important aspects related to the oldest old complex patients, and how to manage those patients.
Export Options
About this article
Cite this article as:
Colloca G., Corsonello A., Marzetti E., Balducci L., Landi F., Extermann M., Scambia G., Cesari M., Carreca I., Monfardini S. and Bernabei R., Treating Cancer in Older and Oldest Old Patients, Current Pharmaceutical Design 2015; 21 (13) . https://dx.doi.org/10.2174/1381612821666150130122536
DOI https://dx.doi.org/10.2174/1381612821666150130122536 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Cardiovascular Effects of Ghrelin and Growth Hormone Secretagogues
Cardiovascular & Hematological Disorders-Drug Targets The Pathophysiology of Heart Failure in Children: The Basics
Current Cardiology Reviews Role of Pharmacotherapy in Cardiac Ion Channelopathies
Current Vascular Pharmacology Design, Synthesis and Biological Evaluation of Antipicornaviral Pyrrole-Containing Peptidomimetics
Protein & Peptide Letters Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews H19: A Vital Long Noncoding RNA in the Treatment of Diabetes and Diabetic Complications
Current Pharmaceutical Design Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Editorial [Hot topic: Crucial Role of Redox Signaling in the Regulation of Heart Health (Guest Editor: Dipak K. Das)]
Current Cardiology Reviews Obstructive Sleep Apnea and Atrial Arrhythmogenesis
Current Cardiology Reviews Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Cardiac Regeneration by Progenitor Cells: What Is It Known as and What Is It Still to Be Known as?
Cardiovascular & Hematological Agents in Medicinal Chemistry Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology The LIM Protein fhlA is Essential for Heart Chamber Development in Zebrafish Embryos
Current Molecular Medicine Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy Hypocholesterolemia
Current Vascular Pharmacology New Developments in Anthracycline-Induced Cardiotoxicity
Current Medicinal Chemistry The Role of Autophagy in Subarachnoid Hemorrhage: An Update
Current Neuropharmacology